Compare BridgeBio Pharma Inc (BBIO) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs CarMax, Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while CarMax, Inc trades at $58.03 (market cap $8.34B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BBIO | KMX | |
|---|---|---|
Market Cap | $16.61B | $8.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $62.17 |
52-Week Low | $47.29 | $30.88 |
Enterprise Value | $18.16B | $26.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
CarMax (KMX) trades at $58.18, up 0.21% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance, beating expectations in Q3 2025 and Q1 2026 but missing in Q2 2025. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, while net income margin improved slightly to 1.89%. Recent news includes partnerships to enhance customer experience and ongoing legal investigations into fiduciary duties.
Outlook is cautious with a consensus price target of $53.09 below the current price, indicating potential downside. Opportunities lie in operational improvements and AI integrations, but risks include high debt, competitive pressures, and legal scrutiny. Analyst sentiment is neutral with 68.58% hold ratings, suggesting wait-and-see approach amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
